睿知中国医院研究地图
候选清单

正在招募肺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 22 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 22

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心北京医院Beijing Hospital北京医院页面
  2. 研究中心中国人民解放军总医院Chinese PLA General Hospital北京医院页面
  3. 研究中心广州医科大学附属第一医院First Affiliated Hospital of Guangzhou Medical University广州医院页面
  4. 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
  5. 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
  6. 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
  7. 研究中心湖北省肿瘤医院Hubei Cancer Hospital武汉医院页面
  8. 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
  9. 研究中心江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面
  10. 研究中心吉林省肿瘤医院Jilin Cancer Hospital长春医院页面
  11. 研究中心LinYi Cancer Hospital临沂医院页面
  12. 研究中心南京鼓楼医院Nanjing Drum Tower Hospital南京医院页面
  13. 研究中心中国医学科学院肿瘤医院National Cancer Center / Cancer Hospital, CAMS北京医院页面
  14. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  15. 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
  16. 研究中心上海市胸科医院Shanghai Chest Hospital上海医院页面
  17. 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
  18. 研究中心浙江大学医学院附属邵逸夫医院Sir Run Run Shaw Hospital杭州医院页面
  19. 研究中心温州医科大学附属台州医院Taizhou Hospital, Wenzhou Medical University台州医院页面
  20. 研究中心四川大学华西医院West China Hospital成都医院页面
  21. 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面
  22. 研究中心复旦大学附属中山医院Zhongshan Hospital, Fudan University上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06452277,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 3

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(3 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. b. superficial bladder cancer (Ta, Tis and T1),

    排除标准第 3 条

  3. No prior systemic therapy for locally advanced or metastatic disease. No prior treatment with a HER2 ex20ins-targeted therapy (e.g. poziotinib, trastuzumab deruxtecan). Participants who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the start of screening.

    入选标准第 4 条

    Inability to discontinue treatment with chronic systemic corticosteroids. Participants who require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study. Replacement therapy (e.g., physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is acceptable, provided that the dose is stable for >4 weeks prior to planned start of study intervention.

    排除标准第 7 条

    Prior radiotherapy outside of the brain within 21 days before of planned start of study intervention. Participants must have recovered from all radiation-related toxicities and not require corticosteroids.

    排除标准第 10 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06452277,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Participant must be ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signing the informed consent.
  2. Documented histologically or cytologically confirmed locally advanced non-squamous NSCLC, not suitable for definitive therapy or metastatic non-squamous NSCLC at screening (small cell or mixed histologies are excluded) (Stage III-IV NSCLC).
  3. Documented activating HER2 mutation in the tyrosine kinase domain (TKD) assessed by tissue molecular test in a CLIA-certified (US sites) or an equally accredited (outside of the US) local laboratory. However, participants may be included at the discretion of the investigator if the laboratory performing the assay is not CLIA or similar certified but the laboratory is locally accredited.
  4. No prior systemic therapy for locally advanced or metastatic disease. No prior treatment with a HER2 ex20ins-targeted therapy (e.g. poziotinib, trastuzumab deruxtecan). Participants who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the start of screening.
  5. Eligible to receive treatment with the selected platinum-based doublet-chemotherapy (i.e. cisplatin/pemetrexed or carboplatin/pemetrexed) and pembrolizumab in accordance with the SmPC/Product Information.

排除标准:Exclusion Criteria:

  1. Known history of prior malignancy except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for five years since initiation of that therapy. Exception: the following cancer types are acceptable within five years if curatively treated or under surveillance:
  2. a. in situ cancers of cervix, breast, or skin,
  3. b. superficial bladder cancer (Ta, Tis and T1),
  4. c. limited-stage prostate cancer,
  5. d. basal or squamous cancers of the skin.
  6. Tumors with targetable alterations with approved available therapy, with the exception of HER2 mutation in the TKD.
  7. Inability to discontinue treatment with chronic systemic corticosteroids. Participants who require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study. Replacement therapy (e.g., physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is acceptable, provided that the dose is stable for >4 weeks prior to planned start of study intervention.
  8. Pre-existing peripheral neuropathy that is Grade ≥2 by CTCAE (v5.0).
  9. History of severe hypersensitivity reaction to treatment with a monoclonal antibody.
  10. Prior radiotherapy outside of the brain within 21 days before of planned start of study intervention. Participants must have recovered from all radiation-related toxicities and not require corticosteroids.

引自 ClinicalTrials.gov, NCT06452277, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06452277,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06452277